The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes

Necela, Brian M.; Axenfeld, Bianca C.; Serie, Daniel J.; Kachergus, Jennifer M.; Perez, Edith A.; Thompson, E. Aubrey; Norton, Nadine

doi:10.1186/s40169-016-0133-2

Clinical and Translational Medicine

Table 1 76 genes were differentially expressed in both ERBB2-overexpressing cancer cell lines and iPSC-derived cardiomyocytes, following treatment with trastuzumab, p < 0.05

From: The antineoplastic drug, trastuzumab, dysregulates metabolism in iPSC-derived cardiomyocytes

Gene	ERBB2-overexpressing cancer cell lines			iPSC-derived cardiomyocytes
Gene	logCPM	FC	p value	logCPM	FC	p value
DDX60	4.37	1.31	2.32E−04	4.42	1.68	0.001
GABRP	3.10	1.43	0.032	0.51	2.46	0.001
DHCR24	9.72	0.82	0.001	5.84	0.68	0.002
DHCR7	7.60	0.75	1.06E−04	4.53	0.70	0.002
BMF	5.23	1.49	1.49E−04	6.86	1.48	0.002
PTPRE	2.23	1.27	0.036	3.21	1.71	0.002
INSIG1	6.79	0.72	9.13E−05	4.21	0.72	0.003
TYMS	5.54	0.81	0.030	6.02	0.67	0.003
SCD	10.80	0.59	0.000	6.18	0.69	0.004
ZNF90	1.88	0.66	0.039	2.21	0.70	0.006
SEMA6C	3.01	1.80	0.001	6.18	1.36	0.006
PRSS23	6.64	1.22	6.12E−04	4.95	1.38	0.006
CDK1	7.12	0.80	0.023	5.25	0.70	0.007
REPS2	4.96	1.15	0.021	4.96	1.46	0.007
LDLR	7.78	0.81	1.63E−04	5.84	0.66	0.007
YARS	7.38	0.89	0.027	6.97	0.79	0.007
MSMO1	6.95	0.80	0.002	5.51	0.72	0.008
UBE2T	5.57	0.87	0.023	4.74	0.71	0.012
SEPP1	5.87	1.32	0.006	5.56	1.29	0.015
SREBF1	9.23	0.85	0.008	4.06	0.69	0.015
CLU	8.72	1.23	9.44E−04	5.81	1.37	0.016
TOMM40	6.91	0.84	0.002	5.37	0.74	0.017
ABCA1	2.46	1.43	0.003	5.32	1.48	0.017
NSDHL	5.41	0.84	0.004	4.22	0.77	0.018
KIF18B	5.33	0.78	0.014	3.52	0.70	0.018
ERO1LB	4.05	1.21	0.025	3.76	1.35	0.019
NEIL3	4.17	0.80	0.036	1.84	0.66	0.019
HIST2H2BE	5.09	1.20	0.019	6.96	1.34	0.019
TUBA1B	7.79	0.81	0.015	7.92	0.75	0.021
FDPS	7.37	0.80	0.001	5.83	0.82	0.022
ERV3-1	3.53	1.18	0.027	3.95	1.38	0.023
ACAT2	5.76	0.72	0.002	4.80	0.74	0.024
PPL	6.33	1.11	0.048	4.97	1.38	0.024
NBR1	7.15	1.12	0.026	7.24	1.25	0.027
PDSS1	3.74	0.75	0.007	2.24	0.72	0.027
CCDC28A	3.39	1.33	6.92E−04	2.38	1.33	0.027
ETNK1	6.47	1.12	0.010	5.65	1.25	0.027
SNAP23	6.44	1.10	0.050	6.19	1.23	0.027
TUBG1	5.00	0.84	0.016	5.01	0.81	0.028
RRS1	5.59	0.85	0.004	3.69	0.72	0.029
MATN2	5.79	1.39	8.99E−04	5.89	1.28	0.032
NCAPH	5.88	0.76	0.007	3.31	0.69	0.032
AKAP3	0.90	1.44	0.033	1.59	1.41	0.032
MPV17L2	3.69	0.81	0.001	4.46	0.77	0.032
PTGES2	6.47	0.89	0.023	5.85	0.74	0.034
WDR4	4.54	0.79	0.005	2.11	0.76	0.036
TXNIP	7.50	1.38	5.31E−04	4.36	1.30	0.037
TOP3A	6.15	0.87	0.007	4.74	0.84	0.038
PDK4	1.08	2.20	1.80E−05	2.77	1.43	0.039
BCAS3	4.46	1.21	0.009	4.42	1.25	0.039
RRM2	8.39	0.76	0.014	5.27	0.77	0.039
CHCHD3	6.22	0.87	0.031	6.56	0.82	0.039
MBNL2	6.95	1.12	0.023	5.89	1.31	0.040
RAB17	5.09	1.17	0.039	2.04	1.50	0.040
BIRC5	6.58	0.79	0.023	4.81	0.70	0.040
PGAM5	6.54	0.82	3.46E−04	5.09	0.80	0.040
IDI1	7.37	0.82	0.003	5.76	0.82	0.043
FADS2	7.15	0.76	0.013	6.90	0.81	0.046
RNASEH2A	5.57	0.85	0.033	3.52	0.69	0.046
NFASC	4.95	1.55	0.005	0.68	1.58	0.048
PAK1IP1	5.00	0.89	0.048	2.88	0.81	0.049
DHFR	6.93	0.86	0.018	6.46	0.82	0.049
FHL1	3.30	1.49	0.041	7.24	1.21	0.050
PRODH	7.11	1.24	0.005	2.43	0.59	0.003
KCNQ5	0.32	0.57	0.019	4.02	1.54	0.006
PIM1	4.28	1.25	0.005	3.68	0.72	0.006
MAP6D1	3.06	1.17	0.038	2.05	0.70	0.011
TLL1	−0.08	0.64	0.049	2.36	1.76	0.013
DYNC1LI1	5.67	0.89	0.022	7.96	1.28	0.015
MXRA5	6.22	0.83	0.019	1.33	1.90	0.015
RILPL2	3.16	1.27	0.012	2.11	0.72	0.023
RPL18A	8.66	1.11	0.028	5.97	0.77	0.032
NAGLU	4.69	1.17	0.023	3.64	0.76	0.034
RNF39	3.05	1.28	0.046	1.04	0.70	0.039
RPS18	9.84	1.11	0.041	8.29	0.76	0.040
ARHGAP18	4.99	1.11	0.040	0.74	0.67	0.048

63/76 genes showed fold changes in the same direction. 13 genes with FC in the opposite direction between cancer cell lines and iPSC-derived cardiomyocytes are listed at the bottom of the table in italics. All genes are ordered by p values in cardiomyocytes
Differential gene expression analyses were performed in six cancer cell lines overexpressing ERBB2 (BT474, HCC1419, HCC1569, HCC1954, MDAMB453 and SKBR3) and in iPSC-derived cardiomyocytes following treatment with trastuzumab
iPSC induced pluripotent stem cell, logCPM log 2 counts per million, FC fold change

Back to article page